reports
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pu...
- Jonathan Moreland
STAA STAAR SURGICAL CO.
MYE MYERS INDUSTRIES INC.
KVHI KVH INDUSTRIES INC.
GOGO GOGO INC.
GLP GLOBAL PARTNERS LP
FAST FASTENAL COMPANY
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CNS COHEN & STEERS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
SONO SONOS
AEYE AUDIOEYE INC
AVTR AVANTOR
TELA INC.
UTZ TELA BIO
ACVA UTZ BRANDS INC (A)
NEXT ACV AUCTIONS INC.
EVLV NEXT CAPITAL
BHVN EVOLV TECHNOLOGIES HLDGS INC
VANI BIOHAVEN LTD
WEST VIVANI MEDICAL INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
ET GRAN TIERRA ENERGY INC.
MNR ENERGY TRANSFER LP
CRVO MACH NATURAL RESOURCES LP
NCDL CERVOMED INC
SPRU NUVEEN CHURCHILL DIRECT LENDING CORP
MXF SPRUCE POWER HOLDING CORP
GF THE MEXICO FUND
HYMC INC.
BATRK THE NEW GERMANY FUND
GMRE INC.
ANNX HYCROFT MINING HOLDING CORPORATION
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Co...
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, In...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
KVHI KVH INDUSTRIES INC.
GLP GLOBAL PARTNERS LP
FOXF FOX FACTORY HOLDING CORP.
FLDM FLUIDIGM
ALG ALAMO GROUP INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
TREX TREX COMPANY INC.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
HFFG HF FOODS GROUP INC
AVTR AVANTOR
PGNY INC.
TELA PROGYNY
SMCI TELA BIO
MRVI SUPER MICRO COMPUTER
BLND INC.
BHVN MARAVAI LIFESCIENCES HOLDINGS
DRCT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
VANI BIOHAVEN LTD
GTE DIRECT DIGITAL HLDGS INC
GT VIVANI MEDICAL INC
CRVO GRAN TIERRA ENERGY INC.
NCDL GOODYEAR TIRE & RUBBER CO.
NEXT CERVOMED INC
CATX NUVEEN CHURCHILL DIRECT LENDING CORP
RMI NEXTSOURCE MATERIALS INC.
BATRK PERSPECTIVE THERAPEUTICS
GMRE INC.
RIVERNORTH OPPOR MUN INC FD INC
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a gra...
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Di...
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering p...
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing ...
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highli...
TELA Bio to Announce Third Quarter 2025 Financial Results
TELA Bio to Announce Third Quarter 2025 Financial Results MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInve...
TELA Bio Appoints William Plovanic to Board of Directors
TELA Bio Appoints William Plovanic to Board of Directors MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William (“Bill”) Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as Managing Director, Healthcare Equity ...
TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors ...
TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a nationally recognized healthcare leader and ...
TELA Bio Reports Second Quarter 2025 Financial Results
TELA Bio Reports Second Quarter 2025 Financial Results MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix produ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted ...
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Co...
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio...
TELA Bio to Announce Second Quarter 2025 Financial Results
TELA Bio to Announce Second Quarter 2025 Financial Results MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInves...
- Wedbush Research
MNKD MANNKIND CORP.
GOOGL ALPHABET INC. CLASS A
BCRX BIOCRYST PHARMACEUTICALS INC.
ACRS ACLARIS THERAPEUTICS INC.
PTGX PROTAGONIST THERAPEUTICS
ZG ZILLOW GROUP INC. CLASS A
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
COGT COGENT BIOSCIENCES INC
RKT ROCKET COMPANIES
APGE APOGEE THERAPEUTICS INC
- Jay McCanless
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units coveri...
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for ...
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair Based on market research, inguinal hernia repair is the most common type of hernia repair MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. T...
TELA Bio Appoints Jeffrey Blizard as President
TELA Bio Appoints Jeffrey Blizard as President Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio’s Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. “...
- Wedbush Research
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
SBRA SABRA HEALTH CARE REIT INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NHI NATIONAL HEALTH INVESTORS INC.
LTC LTC PROPERTIES INC.
WELL WELLTOWER INC.
CTRE CARETRUST REIT INC
BMRN BIOMARIN PHARMACEUTICAL INC.
SKY SKYLINE CHAMPION CORPORATION
TMHC TAYLOR MORRISON HOME CORPORATION
PTGX PROTAGONIST THERAPEUTICS
CVCO CAVCO INDUSTRIES INC.
VTR VENTAS INC.
ISR ISORAY
ZG ZILLOW GROUP INC. CLASS A
YMAB Y-MABS THERAPEUTICS
RKT ROCKET COMPANIES
STRW STRAWBERRY FIELDS REIT INC.
BCAX BICARA THERAPEUTICS INC.
CAMP CAMP4 THERAPEUTICS CORPORATION
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.